利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

207 条记录 (耗时 0.023 秒)

    GADOLINIUM CHELATE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
    1.
    发明公开
    GADOLINIUM CHELATE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 审中-公开

    公开(公告)号：EP4317206A1

    公开(公告)日：2024-02-07

    申请号：EP21932636.0

    申请日：2021-11-01

    申请人： SUZHOU ZHECI PHARMACEUTICAL TECHNOLOGY CO., LTD. ,  Southern Medical University

    发明人： SHEN, Zheyu ,  LU, Yudie

    IPC分类号： C08F8/42 ,  A61K49/12 ,  A61K49/14 ,  C08B37/08

    摘要： A gadolinium chelate, a preparation method therefor, and an application thereof. The gadolinium chelate is a complex formed by chelation of gadolinium ions and macromolecules. The macromolecules comprise any one of or a copolymer or mixture of two or more of carboxylic acid-containing high-molecular polymers, amino-containing high-molecular polymers, hydroxyl-containing high-molecular polymers, polyester high-molecular polymers, polyether high-molecular polymers, polyamide high-molecular polymers, proteins, polypeptides, and polysaccharides. The gadolinium ions and the macromolecules form the gadolinium chelate by means of chelation. The gadolinium chelate is a water-soluble macromolecular drug, can improve a longitudinal relaxation rate r 1 and reduce a ratio of r 2 /r 1 , has good water-solubility and high stability, and meanwhile, can exhibit a good imaging effect in a short period of time and shorten an MRI time.

    NANOSTRUCTURES AND APPLICATIONS THEREOF
    2.
    发明公开
    NANOSTRUCTURES AND APPLICATIONS THEREOF 审中-公开

    公开(公告)号：EP4241792A1

    公开(公告)日：2023-09-13

    申请号：EP22160879.7

    申请日：2022-03-08

    申请人： Spago Nanomedical AB

    发明人： AXELSSON, Oskar ,  EKENGARD, Erik ,  LIU, Yi-Chi ,  PARIS, Juraj

    IPC分类号： A61K49/12 ,  A61K49/18

    摘要： The present disclosure relates to a plurality of globular nanostructures, having a dispersity between 1 and 1.8 and a volume average hydrodynamic diameter of 13 nm to 90 nm; wherein each nanostructure comprises a polymer framework of monomer residues, wherein the average number of bonds from each monomer residue is in the range of from 3.0 up to but not including 6.0; wherein at least 90% of the monomer residues comprise two geminal chelating groups, each chelating group independently being -PO(OR 1 )(OR 2 ); wherein R 1 and R 2 are independently selected from the group consisting of a negative charge and H; and - denotes an internal bond in the monomer residue. The present disclosure also relates to a method of producing such nanostructures, to the use of such nanostructures as well as to a pharmaceutical composition comprising such nanostructures.